Phase i adjuvant trial of sorafenib in patients with hepatocellular carcinoma after orthotopic liver transplantation

Anticancer Research

Volumn 33, Issue 6, 2013, Pages 2797-2800

  Jia, Ning ^a   Liou, Iris ^b   Halldorson, Jeffrey ^b   Carithers, Robert ^b   Perkins, James ^b   Reyes, Jorge ^b   Yeh, Matthew ^c   Stohr, Elizabeth ^c   Rao, Sujata ^c,d   Lin, Edward H ^c  

^a TSINGHUA UNIVERSITY   (China)

^b UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF WASHINGTON   (United States)

^d ONYX PHARMACEUTICALS   (United States)

Author keywords

Adjuvant therapy; Hepatocellular carcinoma; Orthotopic liver transplantation; Phase I; Sorafenib

Indexed keywords

ACICLOVIR; CLOTRIMAZOLE; COTRIMOXAZOLE; FLUCONAZOLE; GANCICLOVIR; RAPAMYCIN; SORAFENIB; TACROLIMUS; ANTINEOPLASTIC AGENT; CARBANILAMIDE DERIVATIVE; DRUG DERIVATIVE; NICOTINAMIDE;

ADULT; AGED; ARTICLE; ASCITES; CANCER PATIENT; CANCER SURGERY; CASE REPORT; CLINICAL ASSESSMENT; COHORT ANALYSIS; COLITIS; DIARRHEA; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG ERUPTION; DRUG SAFETY; EXPLANT; FATIGUE; FEMALE; HAND FOOT SYNDROME; HERPES VIRUS INFECTION; HIGH RISK PATIENT; HUMAN; HYPERTENSION; INSOMNIA; LEUKOPENIA; LIVER CELL CARCINOMA; LIVER TRANSPLANTATION; MALE; MYCOSIS; PAIN; PERIPHERAL EDEMA; PHASE 1 CLINICAL TRIAL; PNEUMOCYSTIS PNEUMONIA; PRIORITY JOURNAL; PRURITUS; SENSORY NEUROPATHY; TREATMENT OUTCOME; ADJUVANT THERAPY; ADOLESCENT; LIVER TUMOR; MIDDLE AGED; PHASE I; TUMOR RECURRENCE;

ADJUVANT THERAPY; HEPATOCELLULAR CARCINOMA; ORTHOTOPIC LIVER TRANSPLANTATION; PHASE I; SORAFENIB;

ADOLESCENT; AGED; ANTINEOPLASTIC AGENTS; CARCINOMA, HEPATOCELLULAR; FEMALE; HUMANS; LIVER NEOPLASMS; LIVER TRANSPLANTATION; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NIACINAMIDE; PHENYLUREA COMPOUNDS; TREATMENT OUTCOME;

MLCS; MLOWN;

EID: 84881323974     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (15)

1. Roayaie S, Schwartz JD, Sung MW, Emre SH, Miller CM, Gondolesi GE, Krieger NR and Schwartz ME: Recurrence of hepatocellular carcinoma after liver transplant: Patterns and prognosis. Liver Transpl 10: 534-540, 2004.
2. Grasso A, Stigliano R, Morisco F, Martines H, Quaglia A, Dhillon AP, Patch D, Davidson BR, Rolles K and Burroughs AK: Liver transplantation and recurrent hepatocellular carcinoma: Predictive value of nodule size in a retrospective and explant study. Transplantation 81: 1532-1541, 2006.
3. Chan EY, Larson AM, Fix OK, Yeh MM, Levy AE, Bakthavatsalam R, Halldorson JB, Reyes JD and Perkins JD: Identifying risk for recurrent hepatocellular carcinoma after liver transplantation: Implications for surveillance studies and new adjuvant therapies. Liver Transpl 14: 956-965, 2008.
4. Kim R, Tan A, Estfan B and Aucejo F: Adjuvant treatment after orthotopic liver transplantation: Is it really necessary? Oncology 23: 1276-1281, 2009.
5. Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, de Oliveira AC, Santoro A, Raoul JL, Forner A, Schwartz M, Porta C, Zeuzem S, Bolondi L, Greten TF, Galle PR, Seitz JF, Borbath I, Haussinger D, Giannaris T, Shan M, Moscovici M, Voliotis D, Bruix J; SHARP Investigators Study Group: Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 359: 378-390, 2008.
6. Cheng AL, Kang YK, Chen Z, Tsao CJ, Qin S, Kim JS, Luo R, Feng J, Ye S, Yang TS, Xu J, Sun Y, Liang H, Liu J, Wang J, Tak WY, Pan H, Burock K, Zou J, Voliotis D and Guan Z: Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: A phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol 10: 25-34, 2009.
7. Cancer Therapy Evaluation Program, Common Terminology Criteria for Adverse Events, Version 3.0, DCTD, NCI, NIH, DHHS, March 31, 2003(http://ctep.cancer.gov), Publish Date: August 9, 2006.
8. Siegel AB, Hidalgo R, Tsushima D , Zaretsky J, Emond J, Kato T and Brown RS: Phase I trial of sorafenib in hepatocellular carcinoma (HCC) patients after liver transplantation (LT). J Clin Oncol 29: abstr TPS172, 2011.
9. Yoon DH, Ryoo BY, Ryu MH, Lee SG, Hwang S, Suh DJ, Lee HC, Kim TW, Ahn CS, Kim KH, Moon DB and Kang YK: Sorafenib for recurrent hepatocellular carcinoma after liver transplantation. Jpn J Clin Oncol 40: 768-773, 2010.
10. Kim R, El-Gazzaz G, Tan A et al: Safety and feasibility of using sorafenib in recurrent hepatocellular carcinoma after orthotopic liver transplantation. Oncology 79: 62-66, 2010.
11. Dharancy S, Romano O, Lohro R, Pageaux GP, Ledinghen VD, Hurtova M, Vanlemmens C, Salame E, Cattan S, Boleslawski E, Mathurin P and Pruvot FR: Tolerability of Sorafenib in recurrent hepatocellular carcinoma after liver transplantation: A case control study. Liver Transpl 14: S216, 2008.
12. Bechstein WO: Neurotoxicity of calcineurin inhibitors: Impact and clinical management. Transpl Int 13: 313-326, 2000.
13. Pokorny H, Gnant M, Rasoul-Rockenschaub S, Gollackner B, Steiner B, Steger G, Steininger R and Muhlbacher F: Does additional doxorubicin chemotherapy improve outcome in patients with hepatocellular carcinoma treated by liver transplantation? Am J Transplant 5: 788-794, 2005.
14. Soderdahl G, Backman L, Isoniemi H, Cahlin C, Hockerstedt K, Broome U, Makisalo H, Friman S and Ericzon BG: A prospective, randomized, multi-centre trial of systemic adjuvant chemotherapy versus no additional treatment in liver transplantation for hepatocellular carcinoma. Transpl Int 19: 288-294, 2006.
15. Xu J, Shen ZY, Chen XG, Zhang Q, Bian HJ, Zhu P, Xu HY, Song F, Yang XM, Mi L, Zhao QC, Tian R, Feng Q, Zhang SH, Li Y, Jiang JL, Li L, Yu XL, Zhang Z and Chen ZN: A randomized controlled trial of Licartin for preventing hepatoma recurrence after liver transplantation. Hepatology 45: 269-276, 2007.